α7 nicotinic acetylcholine receptor-mediated neuroprotection against dopaminergic neuron loss in an MPTP mouse model via inhibition of astrocyte activation

Journal of Neuroinflammation

Weimin Fan¹  Kevin Ellsworth³  Zuhu Huang²  Yaping Han²  Yujian Hui¹  Chenlei Zhu¹  Jie Wu⁴  Jun Hu¹  Yuan Liu² 

[1] Department of Orthopedics, the First Affiliated Hospital of Nanjing Medical University, Guang Zhou Road 300, Nanjing, 210029, China;Department of Infectious Diseases, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China;University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA;Laboratory of Neurophysiology, Barrow Neurological Institute, St. Joseph’s Hospital and Medical Center, Phoenix, AZ, 85013, USA

关键词: Neuroprotection;    Neuroinflammation;    Astrocyte;    Parkinson’s disease;    α7 nicotinic acetylcholine receptor;   

Others  :  1212599
DOI  :  10.1186/1742-2094-9-98

 received in 2012-01-02, accepted in 2012-05-24,  发布年份 2012

【 授权许可】

   
2012 Liu et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Jakowec MW, Petzinger GM: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned model of parkinson’s disease, with emphasis on mice and nonhuman primates. Comp Med 2004, 54:497-513.
• [2]Farina C, Aloisi F, Meinl E: Astrocytes are active players in cerebral innate immunity. Trends Immunol 2007, 28:138-145.
• [3]Hu J, Zhu C, Liu Y, Wang F, Huang Z, Fan W, Wu J: Dynamic alterations of gene expression of nicotinic acetylcholine receptor alpha7, alpha4 and beta2 subunits in an acute MPTP-lesioned mouse model. Neurosci Lett 2011, 494:232-236.
• [4]Liberatore GT, Jackson-Lewis V, Vukosavic S, Mandir AS, Vila M, McAuliffe WG, Dawson VL, Dawson TM, Przedborski S: Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat Med 1999, 5:1403-1409.
• [5]Fan Y, Kong H, Shi X, Sun X, Ding J, Wu J, Hu G: Hypersensitivity of aquaporin 4-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine and astrocytic modulation. Neurobiol Aging 2008, 29:1226-1236.
• [6]Yang YJ, Zhang S, Ding JH, Zhou F, Hu G: Iptakalim protects against MPP+-induced degeneration of dopaminergic neurons in association with astrocyte activation. Int J Neuropsychopharmacol 2009, 12:317-327.
• [7]Quik M: Smoking, nicotine and Parkinson’s disease. Trends Neurosci 2004, 27:561-568.
• [8]de Jonge WJ, Ulloa L: The alpha7 nicotinic acetylcholine receptor as a pharmacological target for inflammation. Br J Pharmacol 2007, 151:915-929.
• [9]Dutta G, Zhang P, Liu B: The lipopolysaccharide Parkinson’s disease animal model: mechanistic studies and drug discovery. Fundam Clin Pharmacol 2008, 22:453-464.
• [10]Gao M, Jin Y, Yang K, Zhang D, Lukas RJ, Wu J: Mechanisms involved in systemic nicotine-induced glutamatergic synaptic plasticity on dopamine neurons in the ventral tegmental area. J Neurosci 2010, 30:13814-13825.
• [11]Turek JW, Kang CH, Campbell JE, Arneric SP, Sullivan JP: A sensitive technique for the detection of the alpha 7 neuronal nicotinic acetylcholine receptor antagonist, methyllycaconitine, in rat plasma and brain. J Neurosci Methods 1995, 61:113-118.
• [12]Zhou F, Wu JY, Sun XL, Yao HH, Ding JH, Hu G: Iptakalim alleviates rotenone-induced degeneration of dopaminergic neurons through inhibiting microglia-mediated neuroinflammation. Neuropsychopharmacology 2007, 32:2570-2580.
• [13]West MJ: New stereological methods for counting neurons. Neurobiol Aging 1993, 14:275-285.
• [14]Shytle RD, Mori T, Townsend K, Vendrame M, Sun N, Zeng J, Ehrhart J, Silver AA, Sanberg PR, Tan J: Cholinergic modulation of microglial activation by alpha 7 nicotinic receptors. J Neurochem 2004, 89:337-343.
• [15]Clark AR, Dean JL, Saklatvala J: Post-transcriptional regulation of gene expression by mitogen-activated protein kinase p38. FEBS Lett 2003, 546:37-44.
• [16]Choi SH, Joe EH, Kim SU, Jin BK: Thrombin-induced microglial activation produces degeneration of nigral dopaminergic neuronsin vivo. J Neurosci 2003, 23:5877-5886.
• [17]Zhang S, Zhou F, Ding JH, Zhou XQ, Sun XL, Hu G: ATP-sensitive potassium channel opener iptakalim protects against MPP-induced astrocytic apoptosis via mitochondria and mitogen-activated protein kinase signal pathways. J Neurochem 2007, 103:569-579.
• [18]Takuma K, Baba A, Matsuda T: Astrocyte apoptosis: implications for neuroprotection. Prog Neurobiol 2004, 72:111-127.
• [19]Allam MF, Del CAS, Navajas RF: Parkinson’s disease, smoking, and gender. Mov Disord 2007, 22:1829-1830.
• [20]Quik M, O’Neill M, Perez XA: Nicotine neuroprotection against nigrostriatal damage: importance of the animal model. Trends Pharmacol Sci 2007, 28:229-235.
• [21]Park HJ, Lee PH, Ahn YW, Choi YJ, Lee G, Lee DY, Chung ES, Jin BK: Neuroprotective effect of nicotine on dopaminergic neurons by anti-inflammatory action. Eur J Neurosci 2007, 26:79-89.
• [22]Takeuchi H, Yanagida T, Inden M, Takata K, Kitamura Y, Yamakawa K, Sawada H, Izumi Y, Yamamoto N, Kihara T, Uemura K, Inoue H, Taniguchi T, Akaike A, Takahashi R, Shimohama S: Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone-induced Parkinson’s disease models. J Neurosci Res 2009, 87:576-585.
• [23]Perez XA, Bordia T, McIntosh JM, Grady SR, Quik M: Long-term nicotine treatment differentially regulates striatal alpha6alpha4beta2* and alpha6(nonalpha4)beta2* nAChR expression and function. Mol Pharmacol 2008, 74:844-853.
• [24]Quik M, Bordia T, O’Leary K: Nicotinic receptors as CNS targets for Parkinson’s disease. Biochem Pharmacol 2007, 74:1224-1234.
• [25]Parain K, Hapdey C, Rousselet E, Marchand V, Dumery B, Hirsch EC: Cigarette smoke and nicotine protect dopaminergic neurons against the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine Parkinsonian toxin. Brain Res 2003, 984:224-232.
• [26]Wu J: Understanding of nicotinic acetylcholine receptors. Acta Pharmacol Sin 2009, 30:653-655.
• [27]Piao WH, Campagnolo D, Dayao C, Lukas RJ, Wu J, Shi FD: Nicotine and inflammatory neurological disorders. Acta Pharmacol Sin 2009, 30:715-722.
• [28]Cui WY, Li MD: Nicotinic modulation of innate immune pathways via alpha7 nicotinic acetylcholine receptor. J Neuroimmune Pharmacol 2010, 5:479-488.
• [29]Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, Li JH, Wang H, Yang H, Ulloa L, Al-Abed Y, Czura CJ, Tracey KJ: Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-388.
• [30]Yoshikawa H, Kurokawa M, Ozaki N, Nara K, Atou K, Takada E, Kamochi H, Suzuki N: Nicotine inhibits the production of proinflammatory mediators in human monocytes by suppression of I-kappaB phosphorylation and nuclear factor-kappaB transcriptional activity through nicotinic acetylcholine receptor alpha7. Clin Exp Immunol 2006, 146:116-123.
• [31]Sedelis M, Schwarting RK, Huston JP: Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav Brain Res 2001, 125:109-125.
• [32]Furuya T, Hayakawa H, Yamada M, Yoshimi K, Hisahara S, Miura M, Mizuno Y, Mochizuki H: Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. J Neurosci 2004, 24:1865-1872.
• [33]Petroske E, Meredith GE, Callen S, Totterdell S, Lau YS: Mouse model of Parkinsonism: a comparison between subacute MPTP and chronic MPTP/probenecid treatment. Neuroscience 2001, 106:589-601.